Bicycle Therapeutics (BCYC) Non-Current Deffered Revenue (2018 - 2026)

Bicycle Therapeutics' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $34.3 million for Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 58.23% year-over-year to $34.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.3 million (down 58.23% YoY) and the FY2025 annual result came in at $35.5 million, down 61.18% from the prior year.
• Non-Current Deffered Revenue was $34.3 million for Q1 2026 at Bicycle Therapeutics, down from $35.5 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $115.1 million in Q2 2023 and bottomed at $34.3 million in Q1 2026.
• A 5-year average of $75.5 million and a median of $82.9 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2023 — Non-Current Deffered Revenue jumped 165.87% — and 2025, when it slumped 61.18%.
• Bicycle Therapeutics' Non-Current Deffered Revenue stood at $41.5 million in 2022, then surged by 165.87% to $110.2 million in 2023, then dropped by 17.01% to $91.5 million in 2024, then plunged by 61.18% to $35.5 million in 2025, then retreated by 3.29% to $34.3 million in 2026.
• Business Quant data shows BCYC's Non-Current Deffered Revenue at $34.3 million in Q1 2026, $35.5 million in Q4 2025, and $74.1 million in Q3 2025.